Alleviation of hyperlipidemia, insulin resistance, and myopathy by nano selenium/ nano CoQ10 platform with simvastatin in hyperlipidemic rats; comprehensive outlook

Le résumé fourni par la source

Abstract In the present work seeks to address the role of nanoencapsulated platform of Coenzyme Q10 (coQNPs) or selenium (SeNPs) in hyperlipidemia and alleviation of simvastatin-induced myopathy and adverse reactions. Physicochemical characters and zeta potential studies for solid nanoparticles (SLNPs), coQNPs and SeNPs were performed. Male Wistar albino rats were treated for 112 days with either (i) nano-vehicle only (ii) high fat diet (HFD) (iii) HFD + SV (20 mg/kg/day, P.O.) alone or (iv) with coQNPs (10mg/Kg/day, P.O.) or (v) / and (vi) SeNPs (0.1 mg/Kg/day, P.O.) for last 30 days. CoQNPs and SeNPs were shown in a uniform spherical shape with EE% 91.20 ±2.14, 94.89 ±1.54, respectively. HFD resulted in severe changes in all tested parameters that affirmed with histopathological results. Treatment with SV and CoQNPs/ or SeNPs exhibited a prominent restoring of all measured patterns, but the triple combination of SV, CoQNPs, and SeNPs exhibited an intense hepatic and muscular injury. SV and SeNPs treatment showed a pronounced improvement like control itself. These results represent that CoQNPs or SeNPs platforms showed advanced alleviation of hyperlipidemia, insulin resistance, with a direct limitation for its adverse effects such as myopathy and hepatotoxicity.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.